IBI3003

DRUG3 trials

Sponsors

Innovent Biologics (Suzhou) Co. Ltd., Fortvita Biologics (USA)Inc.

Conditions

Multiple MyelomaRelapsed or Refractory Multiple Myeloma

Phase 1

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

RecruitingNCT06083207

Innovent Biologics (Suzhou) Co. Ltd.Multiple Myeloma

Start: 2024-07-29End: 2027-10-31Target: 116Updated: 2024-12-13

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

Not yet recruitingNCT07336472

Fortvita Biologics (USA)Inc.Multiple Myeloma

Start: 2026-04-01End: 2028-09-30Target: 360Updated: 2026-02-25

Phase 3

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

Not yet recruitingNCT07623798

Innovent Biologics (Suzhou) Co. Ltd.Relapsed or Refractory Multiple Myeloma

Start: 2026-06-05End: 2029-12-31Target: 255Updated: 2026-06-03

Related Papers

Initial Results of the first-in-human Phase 1 study of IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA and CD3, in patients with relapsed or refractory multiple myeloma

Blood2025-11-03